

Epidiolex (Cannabidiol) in Treatment Resistant Epilepsy

Orrin Devinsky¹, Joseph Sullivan², Daniel Friedman¹, Elizabeth Thiele³, Eric Marsh⁴, Linda Laux⁵, Ian Miller⁶, Robert Flamini⁷, Angus Wilfong⁸, Francis Filloux⁵,
 Matthew Wong¹⁰, Nicole Tilton², Patricia Bruno³, Rebecca Kamens⁴, Jane Maclean⁴, Judith Bluvstein¹, Srishti Nangia⁵, Anup Patel¹¹, Maria Roberta Cilio²
¹NYU Epilepsy Center, ²UCSF Benioff Children's Hospital, ³MassGeneral Hospital for Children,
⁴Children's Hospital of Philadelphia, ⁵Lurie Children's Hospital, ⁶Miami Children's Hospital, ⁷Pediatric and Adolescent Neurodevelopmental Associates (Atlanta GA), ⁸Texas Children's Hospital, ⁹University of Utah Medical Center, ¹⁰Wake Forest School of Medicine, ¹¹Nationwide Children's Hospital

STUDY OVERVIEW

Cannabidiol (CBD) is the most abundant non-psychoactive cannabinoid in cannabis. Animal studies demonstrate anticonvulsant efficacy in multiple species and models.¹ Anecdotal reports suggest CBD to be effective in children with treatment-resistant epilepsies (TRE), especially Dravet syndrome (DS)². We report results of an open label study in children with TRE in an expanded access treatment program conducted in the US under INDs.

Efficacy results are reported for all patients who received at least 12 weeks of treatment (n=137). Safety results are reported for all patients who received any treatment (n=213)

METHODS

Children and young adults with severe, childhood onset TRE were enrolled in a prospective interventional study (under expanded access INDs) of CBD. Patients entered a 4 week baseline period when parents/caregivers kept seizure diaries, noting all countable motor seizures. Patients then received a >99% pure, oil-based CBD extract of constant composition (Epidiolex: GW Pharma)

Inclusion criteria were:

- Early onset TRE
 - Up to 4 concomitant AEDs (not including Ketogenic diet or VNS)
 - No significant laboratory abnormalities
 - Age 1 year or older
- Prior to starting CBD, a 4 week seizure diary was kept, noting all countable motor seizure types with no changes in medication.
- At Week 4, CBD at 2-5 mg/kg/day was added to the baseline AED regimen, then titrated weekly by 2-5mg/kg increments until intolerance or a maximum dose of 25 mg/kg/day.
- Labs for hematologic, liver, kidney function, and AED levels were performed at baseline, and after 4, 8 and 12 weeks of CBD therapy.

RESULTS

Patient Profile

- 137 patients received ≥3 months of CBD (Table 1)
 - Dravet Syndrome – 25 patients
 - Lennox-Gastaut Syndrome (LGS) – 22 patients
- 48 received ≥ 24 weeks of treatment.
- Safety data was from 213 patients treated for 58.6 patient-years at 11 sites.
- Average # of concomitant AEDs was 3

Table 1

N = 137	Mean	Median	Range
Age (years)	10.8	10.5	2 – 26
Weight (kg)	36.4	32.2	8.8 – 83.2
Female: Male	69:68		
Baseline convulsive seizures/month	95.3	29.5	0 - 1219

Diagnoses

- There was a range of treatment resistant epilepsy subtypes, of which the most common diagnoses were Dravet syndrome in 18% and Lennox Gastaut syndrome in 16%.

Efficacy

- After 12 weeks of treatment, overall seizure frequency was reduced by 54% in all patients, and by 63% in DS patients (Figure 1).
- 50% responder analysis for total seizures are summarized on Figure 2.
- At 3 months 9% of all patients and 16% of DS patients were seizure free.
- Among the 27 pts with atonic seizures, a 66.7% median reduction was noted over 12 weeks of treatment.
- Co-treatment with clobazam was associated with a higher rate of treatment response (>50% reduction in convulsive seizure frequency at 3 mos): 53% on clobazam versus 29% not on clobazam. This could reflect elevations of the nordesmethyl-clobazam metabolite.³

Fig. 1: Median % Reduction in Total Seizures





Fig 2. 50% Responder Analysis – Total Seizures



Safety

- AEs in ≥10% patients were somnolence (21%), diarrhea (17%), fatigue (17%), and decreased appetite (16%).
- 10 patients (5%) discontinued treatment due to an AE, 3 of whom subsequently re-started CBD
- 14 patients withdrew due to lack of efficacy.
- Serious Adverse Events (SAEs) were reported in 52 patients (24%), including 2 deaths, neither were deemed related to Epidiolex. 22 patients had SAEs which were deemed possibly related to treatment, including status epilepticus (10), diarrhea (3), weight loss (2), pneumonia (2), lethargy (1), and hepatotoxicity (1).
- There were no clinically significant changes in WBC, or renal function
- Occasional increases in liver transaminases were noted, thought unlikely to be related to CBD.
- Most AEs were mild or moderate and transient

SUMMARY

- Treatment with Epidiolex is associated with a meaningful reduction in seizure frequency in a high proportion of patients with severe TRE. Those who respond early appear to have a prolonged response.
- Seizure freedom occurs in a 9% of all responders, higher in the Dravet cohort.
- There was a substantial reduction in atonic seizures suggesting that Epidiolex may be effective in LGS patients.
- Tolerability seems good, with a low rate of withdrawals from treatment.

CONCLUSIONS

This open label study found Epidiolex to have a promising efficacy and safety profile in children with a variety of epilepsy syndromes. Children and young adults with Dravet syndrome had the greatest reduction in seizures, but atonic seizures also respond well. Our preliminary data suggests that randomized controlled trials are warranted, and we are pleased to report that these are now ongoing.

References

1. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia* 2014;55:791-802.
2. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy Behav.* 2013; 29: 574-577.
3. Friedman D, Cilio MR, Tilton N, et al. The effect of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. *American Epilepsy Society*, Dec 2014; Seattle, WA.

ACKNOWLEDGEMENTS

We thank GW Pharmaceuticals for providing the medication and support with regulatory and administrative affairs.